Data showed Gilenyaź high efficacy in achieving 'no evidence of disease activity'
Novartis announced new analysis from the phase III FREEDOMS and FREEDOMS II trials. These data showed previously-treated patients with highly-active RMS who were treated with Gilenyaź (fingolimod) had a six-times greater likelihood of achieving 'no evidence of disease activity'. April 21, 2015